摘要
目的:观察白藜芦醇对去卵巢大鼠股骨骨保护素(OPG)及核因子κB受体活化子配体(RANKL)表达的影响。方法:健康3月龄雌性SD大鼠48只,按体重随机分为6组:假手术组(SHAM)、单纯卵巢切除组(OVX)、17β-雌二醇组(ERT,0.1mg.kg-1·d-1)。低、中、高剂量白藜芦醇组(RL、RM、RH,每天分别给予10、20、40mg/kg白藜芦醇)。除假手术组外其余各组均切除双侧卵巢。术后1周开始给药,给药8周后处死所有大鼠,测定股骨骨密度(BMD)及骨生物力学性能:弹性模量(ELASTIC)、刚度(STIFFNESS)、最大应力(M-STRESS)及最大承载力(M-LORD)。用免疫组织化学染色方法观察股骨OPG、RANKL的表达。结果:与OVX组比较,20、40mg·kg-1.d-1白藜芦醇均能上调股骨OPG表达(P<0.05)。与OVX组比较,20、40mg.kg-1·d-1白藜芦醇均下调RANKL的表达,改善股骨骨密度及生物力学性能(P<0.05)。结论:白藜芦醇在体内可上调骨组织中OPG的表达,下调RANKL的表达,这可能是其改善股骨骨密度及生物力学性能的作用机制。
AIM: To study effects of resvemtrol on osteoprotegerin(OPG) and receptor activator of NF-κB ligand(RANKL) expression in femur of ovariectomized rats. METHODS: 48 female SD rats (3 months old) were assigned into 6 groups randomly: sham-operated group(SHAM) ; ovariectomized group(OVX) ; 17β-estradiol replacement therapy group ( ERT, 0.1 mg·kg^- 1·d^- 1, sc) ; high-dose resveratrol-treate group (RH, 40 mg·kg^- 1·d^- 1, i.p. ) ; middle-dose resveratrol-treated group ( RM, 20 mg·kg^- 1·d^- 1, i. p. ) ;low-dose resveratrol-treated group ( RL, 10 mg·kg^-1·d^-1, i. p. ). Except for SHAM group, rats in other groups were operated by bilateral ovariectomy. Administration started at the 8th day after operation and lasted 8 weeks. At the end of the 9th week after operation, all rats were sacrificed. The bone mineral density (BMD) and vitodynamics properties( including ELASTIC, M-STRESS, M-LORD and STIFFNESS) of femurs were measured. The expression of OPG and RANKL in femurs of rats were observed by immunohistochemical staining methods. RESULTS: Compared with OVX group, resveratrol treatment ( 40 mg·kg^-1·d^-1 and 20 mg·kg^-1·d^-1 ) increased expression of OPG in femurs while decreased expression of RANKL in ovariectmized rats. In RH, RM, and ERT group, BMD, ELASTIC, M-STRESS of femurs were higher than those of OVX group. CONCLUSION: Resveratrol increased expression of OPG in femur while decreased expression of RANKL in ovariectmized rats, which was probably one of mechanism that resveratrol improve osteoporosis.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2008年第3期266-270,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics